


Supplemental Figure 1



Supplemental figure 1. Docetaxel and NHS-IL-12 combination therapy increase pro-inflammatory cytokines. Quantification of peripheral IFN- γ , IL-12, TNF α , and KC/GRO in the **(A)** MC38 tumor model in animals treated with docetaxel (red symbols; $n=5$), NHS-IL-12 (blue symbols; $n=5$), docetaxel + NHS-IL-12 (purple symbols; $n=6$) and untreated controls (black symbols; $n=5$) on day 16 post tumor inoculation. Quantification of peripheral IFN- γ , IL-12, TNF α , and KC/GRO in the **(B)** EMT6 tumor model in animals treated with docetaxel (red symbols; $n=15$), NHS-IL-12 (blue symbols; $n=15$), docetaxel + NHS-IL-12 (purple symbols; $n=11$) and untreated controls. Doc = docetaxel. NHS = NHS-IL-12. * = $p<0.05$, ** = $p<0.01$, *** = $p<0.001$, **** = $p<0.0001$.